Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer
Sponsor: Astellas Pharma Inc
Listed as NCT01990196, this PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by Astellas Pharma Inc, it has been updated 15 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- GlaxoSmithKline
- Jonsson Comprehensive Cancer Center
- Medivation, Inc.
- Novartis
- Prostate Cancer Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Los Angeles, United States